Meeting
2020 ASCO Virtual Scientific Program
Neoadjuvant chemotherapy (NACT) and HER2 double inhibition including biosimilar trastuzumab (ONTRUZANT) for HER2-positive early breast cancer (EBC): Population-based real world data from the Danish Breast Cancer Group (DBCG).
Authors
Michael Andersson
Department of Oncology, Rigshospitalet University Hospital, Copenhagen, Denmark
Michael Andersson , Maj-Britt Jensen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 577)
DOI
10.1200/JCO.2020.38.15_suppl.577
Abstract #
577
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2023 ASCO Annual Meeting
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.
First Author: Sonya Chew
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.
First Author: William R Gwin III